SARS-CoV-2-specific ELISA development

• Published in: Journal of immunological methods Vol. 484-485; p. 112832
• Main Authors: Roy, Vicky, Fischinger, Stephanie, Atyeo, Caroline, Slein, Matthew, Loos, Carolin, Balazs, Alejandro, Luedemann, Corinne, Astudillo, Michael Gerino, Yang, Diane, Wesemann, Duane R., Charles, Richelle, Lafrate, A. John, Feldman, Jared, Hauser, Blake, Caradonna, Tim, Miller, Tyler E., Murali, Mandakolathur R., Baden, Lindsey, Nilles, Eric, Ryan, Edward, Lauffenburger, Douglas, Beltran, Wilfredo Garcia, Alter, Galit
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.09.2020; Published by Elsevier B.V
• Subjects: adaptive immunity; antibodies; Antibodies, Viral - blood; Antibodies, Viral - immunology; Antibodies, Viral - isolation & purification; Betacoronavirus - immunology; Betacoronavirus - isolation & purification; Clinical Laboratory Techniques - methods; Coronavirus Infections - blood; Coronavirus Infections - diagnosis; Coronavirus Infections - immunology; Coronavirus Infections - virology; COVID-19; COVID-19 infection; COVID-19 Testing; Enzyme-Linked Immunosorbent Assay; Feasibility Studies; genomics; High-Throughput Screening Assays; Humans; Pandemics; Pneumonia, Viral - blood; Pneumonia, Viral - diagnosis; Pneumonia, Viral - immunology; Pneumonia, Viral - virology; Reproducibility of Results; respiratory system; RNA; SARS-CoV-2; Sensitivity and Specificity; Severe acute respiratory syndrome coronavirus 2; Time Factors; viral shedding; virus replication; viruses
• ISSN: 0022-1759; 1872-7905; 1872-7905
• DOI: 10.1016/j.jim.2020.112832

Critical to managing the spread of COVID-19 is the ability to diagnose infection and define the acquired immune response across the population. While genomic tests for the novel Several Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) detect the presence of viral RNA for a limited time frame, when the virus is shed in the upper respiratory tract, tests able to define exposure and infection beyond this short window of detectable viral replication are urgently needed. Following infection, antibodies are generated within days, providing a durable read-out and archive of exposure and infection. Several antibody tests have emerged to diagnose SARS-CoV-2. Here we report on a qualified quantitative ELISA assay that displays all the necessary characteristics for high-throughput sample analysis. Collectively, this test offers a quantitative opportunity to define both exposure and levels of immunity to SARS-CoV-2.